FDA Approved Drugs by Medical Condition

Search by medical condition for drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Select the letter below that corresponds to the first letter of the medical condition you are searching for and all approved drugs classified under that category will be listed below.

Bacterial Infections

Abthrax (raxibacumab) (by GlaxoSmithKline), Approved December of 2012
For the treatment and prevention of anthrax

Anthim (obiltoxaximab) (by Elusys Therapeutics), Approved March 2016
For the treatment of inhalational anthrax

Avycaz (ceftazidime-avibactam) (by Actavis), Approved February 2015
For the treatment of complicated intra-abdominal and urinary tract infections

Baxdela (delafloxacin) tablets and injection (by Melinta Therapeutics), Approved June 2017
For the treatment of acute bacterial skin and skin structure infections

Cefazolin and Dextrose USP (by B Braun Medical), Approved July 2000
Respiratory tract infections

Dalvance (dalbavancin) (by Durata Therapeutics), Approved May 2014
For the treatment of acute bacterial skin and skin structure infections

Invanz (by Merck), Approved November 2001
Once-daily injectable treatment for bacterial infections

Metronidazole 1.3% Vaginal Gel (by Actavis, Inc.), Approved April 2014
For the treatment of bacterial vaginosis

Omnicef (by Warner-Lambert), Approved December 1997
Treatment against various bacterias

Orbactiv (oritavancin) (by The Medicines Company), Approved August 2014
For the treatment of acute bacterial skin and skin structure infections

Sirturo (bedaquiline) (by Janssen Therapeutics), Approved December 2012
For the treatment of multi-drug resistant tuberculosis

Sivextro (tedizolid phosphate) (by Cubist Pharmaceuticals), Approved June 2014
For the treatment of acute bacterial skin and skin structure infections

Solosec (secnidazole) (by Symbiomix Therapeutics), Approved September 2017
For the treatment of bacterial vaginosis

Spectracef (by TAP Pharmaceuticals), Approved August 2001
Oral tablets for the treatment of mild to moderate bacterial infections

Synercid I.V. (by Rhone Poulenc Rorer), Approved September 1999
quinupristin and dalfopristin for injection

Teflaro (ceftaroline fosamil) (by Cerexa), November 2010
For the treatment of bacterial skin infections and bacterial pneumonia

Trovan (by Pfizer), Approved December 1997
Treatment for bacterial infections

Vaxchora (Cholera Vaccine, Live, Oral) (by PaxVax), Approved June 2016
For active immunization against Cholera

Vibativ (telavancin) (by Theravance), Approved June 2013
For the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by staph aureus

Vibativ (telavancin) (by Theravance), Approved September 2009
For the treatment of complicated skin and skin structure infections

Zerbaxa (ceftolozane + tazobactam) (by Cubist Pharmaceuticals), Approved December 2014
For the treatment of complicated intra-abdominal and urinary tract infections

Zinplava (bezlotoxumab) (by Merck), Approved October 2016
For the treatment of recurrent Clostridium difficile infection in patients receiving antibacterial treatment

Batten Disease

Brineura (cerliponase alfa) (by BioMarin), Approved April 2017
For the treatment of late infantile neuronal ceroid lipofuscinosis type 2

Benign Prostatic Hyperplasia (Enlarged Prostate)

Dutasteride (by GlaxoSmithKline), Approved November 2001
For the treatment of symptomatic benign prostatic hyperplasia

FLOMAX (by Boehringer Ingelheim), Approved October 1997
Treatment for benign prostatic hypertrophy (BPH)

Jalyn (dutasteride + tamsulosin) (by GlaxoSmithKline), Approved June 2010
For the treatment of benign prostatic hyperplasia

UroXatral (alfuzosin HCl extended-release tablets) (by Sanofi-aventis), Approved June 2003
For the treatment of of the signs and symptoms of benign prostatic hyperplasia

Bipolar Disorder

Saphris (asenapine) (by Schering-Plough), Approved August of 2009
For the treatment of schizophrenia and manic or mixed bipolar 1 episodes

Stavzor (valproic acid delayed release) (by Banner Pharmacaps), Approved July 2008
For the treatment of bipolar manic disorder, seizures and migraine headaches

Vraylar (cariprazine) (by Allergan), Approved September 2015
For the treatment of schizophrenia and bipolar disorder

Bladder Cancer

Tecentriq (atezolizumab) (by Genentech), Approved May 2016
For the treatment of urothelial carcinoma and metastatic non-small cell lung cancer

Bladder Carcinoma

Imfinzi (durvalumab) (by AstraZeneca), Approved May 2017
For the treatment of advanced or metastatic urothelial carcinoma

Bladder Disorders

Detrol (tolterodine tartrate) (by Pharmacia & Upjohn), Approved March 1998
Treatment for an overactive bladder

Detrol LA (tolterodine tartrate) (by Pharmacia & Upjohn), Approved December 2000
For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency

Gelnique (oxybutynin chloride) (by Watson Pharmaceuticals), Approved January 2009
For the treatment of overactive bladder

Mesnex (by Bristol-Myers Squibb, Baxter Healthcare), Approved March 2002
Oral tablet to inhibit the hemorrhagic cystitis induced by Ifex (ifosfamide)

Oxytrol (oxybutynin transdermal system) (by Watson Pharmaceuticals), Approved March 2003
For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Sanctura (trospium chloride) (by Indevus Pharmaceuticals), Approved May, 2004
For the treatment of overactive bladder with symptoms of urge urinary incontinence

Toviaz (fesoterodine fumarate) (by Pfizer), Approved October 2008
For the treatment of overactive bladder

Vesicare (solifenacin succinate) (by Yamanouchi, GlaxoSmithKline), Approved November, 2004
For the treatment of overactive bladder with symptoms of urge urinary incontinence

Blood Cancer

Blincyto (blinatumomab) (by Amgen), Approved December 2014
For the treatment of Philadelphia chromosome-negative relapsed /refractory B cell precursor acute lymphoblastic leukemia

Blood Clots

Kcentra (Prothrombin Complex Concentrate) (by CSL Behring), Approved May 2013
For the reversal of vitamin K antagonist therapy-induced coagulation factor deficiency

Lovenox (enoxaparin sodium) Injection (by Rhone Poulenc Rorer), Approved February 1998
Treatment for prevention of blood clots following hip-replacement surgery

Tretten (Coagulation Factor XIII A-Subunit [Recombinant]) (by Novo Nordisk), Approved December of 2013
For the treatment of congenital factor XIII (FXIII) A-subunit deficiency

Warfarin Sodium tablets (by Barr Laboratories), Approved March 1997
Generic equivalent of Coumadin

Xarelto (rivaroxaban) (by Bayer), Approved July 2011
For the prophylaxis of deep vein thrombosis during knee or hip replacement surgery

Xarelto (rivaroxaban) (by Janssen Pharmaceuticals), Approved November 2011
For the reduction in the risk of stroke and systemic embolism resulting from atrial fibrillation

Blood Transfusions

Ferriprox (deferiprone) (by Apotex), Approved October 2011
For the treatment of transfusional iron overload due to thalassemia

Kcentra (Prothrombin Complex Concentrate) (by CSL Behring), Approved May 2013
For the reversal of vitamin K antagonist therapy-induced coagulation factor deficiency

Bone Diseases

Elelyso (taliglucerase alfa) (by Pfizer), Approved May 2012
For the treatment of Gaucher disease

Strensiq (asfotase alfa) (by Alexion), Approved October 2015
For the treatment of hypophosphatasia

Bone Metastases

Aredia (pamidronate disodium for injection) (by Chiron), Approved August 1996
Treatment for osteolytic bone metastases of breast cancer

Xgeva (denosumab) (by Amgen), Approved November 2010
For the prevention of skeletal-related events in patients with bone metastases from solid tumors

Xofigo (radium Ra 223 dichloride) (by Bayer Healthcare Pharmaceuticals), Approved May 2013
For the treatment of prostate cancer with bone metastases

Zometa (zoledronic acid) (by Novartis), Approved February 2002
For the treatment of multiple myeloma and bone metastases from solid tumors

Bone Neoplasm

Xgeva (denosumab) (by Amgen), Approved June 2013
For the treatment of giant cell tumor of bone

Xgeva (denosumab) (by Amgen), Approved November 2010
For the prevention of skeletal-related events in patients with bone metastases from solid tumors

Bowel Dysfunction

Gattex (teduglutide) (by NPS Pharmaceuticals), Approved December 2012
For the treatment of short bowel syndrome

Brain Cancer

Breast Cancer

Afinitor (everolimus) (by Novartis), Approved April 2012
For the treatment of renal angiomyolipoma associated with tuberous sclerosis complex

Afinitor (everolimus) (by Novartis), Approved July 2012
For the treatment of hormone receptor-positive, HER2-negative breast cancer

Afinitor (everolimus) (by Novartis), Approved March 2009
For the treatment of renal cell carcinoma

Afinitor (everolimus) (by Novartis), Approved May 2011
For the treatment of advanced pancreatic neuroendocrine tumors

Aredia (pamidronate disodium for injection) (by Chiron), Approved August 1996
Treatment for osteolytic bone metastases of breast cancer

Arimidex (anastrozole) (by AstraZeneca), Approved January 1996
Treatment for advanced breast cancer in postmenopausal women

Aromasin Tablets (by Pharmacia & Upjohn), October 21, 1999
Exemestane Tablets, 25 mg

Ellence (by Pharmacia & Upjohn), Approved September 1999
epirubicin hydrochloride

Evista (raloxifene hydrochloride) (by Eli Lilly), Approved September 2007
For the treatment/prevention of osteoporosis and reduction of breast cancer risk in postmenopausal women

Faslodex (fulvestrant) (by AstraZeneca), Approved April 2002
For the treatment of hormone receptor positive metastatic breast cancer

Femara (letrozole) (by Novartis), Approved January 2001
First-line treatment of postmenopausal women with locally advanced or metastatic breast cancer

Femara (letrozole) (by Novartis), Approved July 1997
Treatment for breast cancer

Halaven (eribulin mesylate) (by Eisai), Approved November 2010
For the treatment of metastatic breast cancer

Herceptin (by Genentech), Approved October 1998
Treatment for metastatic breast cancer

Ibrance (palbociclib) (by Pfizer), Approved February 2015
For the treatment of ER-positive, HER2-negative breast cancer

Inform HER-2/neu breast cancer test (by Oncor), Approved January 1998
Treatment for breast cancer prediction

Ixempra (ixabepilone) (by Bristol-Myers Squibb), Approved October 2007
For the treatment of breast cancer

Kadcyla (ado-trastuzumab emtansine) (by Genentech), Approved February 2013
For the treatment of HER2-positive metastatic breast cancer

Kisqali (ribociclib) (by Novartis), Approved March 2017
For the treatment of breast cancer

Perjeta (pertuzumab) (by Genentech), Approved June 2012
For the first-line treatment of HER2+ metastatic breast cancer

Taxotere (Docetaxel) (by Rhone Poulenc Rorer), Approved May 1996
Treatment for locally advanced or metastatic breast cancer

Tykerb (lapatinib) (by GlaxoSmithKline), Approved March 2007
For the treatment of breast cancer

Verzenio (abemaciclib) (by Eli Lilly), Approved September 2017
For the treatment of HR+, HER2- breast cancer

Xeloda (by Roche), Approved April 1998
Treatment for advanced breast cancer tumors

Breast Cancer - HER2 Positive

Nerlynx (neratinib) (by Puma Biotech), Approved July 2017
For the treatment of HER2 breast cancer

Bronchitis

Augmentin (amoxicillin/clavulanate) (by SmithKline Beecham), Approved February 1996
Treatment for infections involving drug-resistant bacteria

Avelox I.V. (moxifloxacin hydrochloride) (by Bayer), Approved November 2001
Injectable antibacterial agent for adults with susceptible strains of bacterial infections

Ceftin (cefuroxime axetil) (by GlaxoSmithKline), Approved September 1997
Treatment of secondary bacterial infections of acute bronchitis

Tudorza Pressair (aclidinium bromide inhalation powder) (by Forest Laboratories), Approved July 2012
For the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease

Burns and Burn Infections

Dermagraft-TC (by Advanced Tissue Sciences), Approved October 1997
Treatment for partial-thickness and severe burns

Sulfamylon (by Mylan Laboratories), Approved June 1998
Treatment used to control bacterial infections on excised burn wounds